New combo therapy aims to shrink lung tumors in hard-to-treat patients
NCT ID NCT07452224
First seen Mar 06, 2026 · Last updated May 01, 2026 · Updated 8 times
Summary
This study tests a new drug (ILKN421H) combined with an existing immunotherapy (pembrolizumab) in 80 adults with advanced non-small cell lung cancer. It includes patients who have not had prior treatment or whose cancer worsened after immunotherapy. The goal is to see if the combination is safe and can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.